Pluri (PLUR) Stock Price, News & Analysis

Company Overview

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Key Stats

• Today's Range: $4.44 to $4.98
• 50-Day Range: $4.20 to $6.04
• 52-Week Range: $3.77 to $8.48
• Volume: 13,535 shs
• Average Volume: 18,464 shs
• Market Capitalization: $26.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Pluri Stock Analysis - MarketRank™

Pluri scored higher than 9% of companies evaluated by MarketBeat, and ranked 910th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Pluri.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pluri is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pluri is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pluri has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.23% of the float of Pluri has been sold short.

Short Interest Ratio / Days to Cover

Pluri has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pluri has recently decreased by 3.41%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pluri does not currently pay a dividend.

Dividend Growth

Pluri does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.23% of the float of Pluri has been sold short.

Short Interest Ratio / Days to Cover

Pluri has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pluri has recently decreased by 3.41%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.48

News Sentiment

Pluri has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pluri this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pluri insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.20% of the stock of Pluri is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 16.59% of the stock of Pluri is held by institutions.

PLUR Stock Analysis - Frequently Asked Questions

How have PLUR shares performed this year?

Pluri's stock was trading at $4.6360 at the beginning of 2024. Since then, PLUR shares have increased by 4.0% and is now trading at $4.82.
View the best growth stocks for 2024 here.

When did Pluri's stock split?

Pluri shares reverse split before market open on Monday, April 1st 2024. The 1-8 reverse split was announced on Monday, April 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Pluri?

Shares of PLUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pluri own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pluri investors own include Block (SQ), Digital Turbine (APPS), Lightning eMotors (ZEV), Archer Aviation (ACHR), ChargePoint (CHPT) and Canoo (GOEV).

Company Calendar

• Today: 12/22/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PLUR
• CUSIP: N/A
• CIK: 1158780
• Web: pluri-biotech.com
• Phone: 972747108600
• Fax: 972-74-710-8787
• Employees: 150
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($6.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,890,000.00
• Net Margins: -4,184.28%
• Pretax Margin: -2,943.46%
• Return on Equity: -917.18%
• Return on Assets: -82.85%

Debt

• Debt-to-Equity Ratio: 4.44
• Current Ratio: 5.90
• Quick Ratio: 5.90

Sales & Book Value

• Annual Sales: $598,000.00
• Price / Sales: 44.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.00 per share
• Price / Book: 4.82

Miscellaneous

• Outstanding Shares: 5,559,000
• Free Float: 4,992,000
• Market Cap: $26.79 million
• Optionable: Optionable
• Beta: 1.64